Navigation Links
Viral Genetics CEO Issues State of the Company Update
Date:2/11/2010

SAN MARINO, Calif., Feb. 11 /PRNewswire-FirstCall/ -- (Pink Sheets: VRAL) -- Our mission is to bring new drug compounds to the marketplace. And we've never been in a stronger position to deliver on that promise. We've built the solid foundation needed to take drug therapies from the laboratory to the marketplace. After years in development, we believe several of our most promising compounds are moving closer to clinical trials.

During 2009, Viral Genetics made significant strides on two fronts -- scientific and financial. Our drug compounds seem to be showing great potential. Additionally, we've built an infrastructure that enables us to use money wisely. We have retired nearly all of our external debt, enabling us to leverage any additional funding to advance new drug therapies -- rather than making interest payments to creditors.

Promising Drug Therapies

HIV/AIDS

Six international, human clinical trials found that our HIV/AIDS drug compound significantly reduced the viral load in some patients. That therapy led to the development of a second generation drug compound called VGV-X. We believe that VGV-X may address the reason that our first HIV/AIDS drug reduced the viral load in some patients, but not others. Preparing this therapeutic approach for human clinical trials will be a top priority during 2010.

Staph, Strep and Sepsis

Our new VGV-S drug compound has been found to provide an alternative to traditional antibiotics in laboratory animals infected with Staphylococcus or with high levels of Streptococcus. Testing during 2009 determined that some infected mice treated with VGV-S, made full recoveries. A control group of sick animals that weren't treated with this therapy either took much longer to recover or did not survive the infections.

The ani
'/>"/>

SOURCE Viral Genetics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. CDC Foundation Launches Viral Hepatitis Action Coalition
2. Viral Genetics Files 2009 3rd Quarter Consolidated Financials and Information Statement at Pinksheets.com
3. Peregrine Pharmaceuticals Awarded Second Broad U.S. Patent for Anti-Viral Applications of Phospholipid-Targeting Antibodies
4. Schering-Plough Reports Potent Antiviral Activity With Narlaprevir (SCH 900518), an Investigational, Once-Daily Protease Inhibitor for Hepatitis C
5. Noninvasive Breath Test Predicts Survival in Patients with Viral Hepatitis
6. Trana Discovery and Southern Research Institute Find Bioactive HIV Antiviral Compounds
7. Peregrine Pharmaceuticals Forms Anti-Viral Research Group to Oversee Its Anti-PS Infectious Disease Collaborations
8. In Vitro Study of Adamas Pharmaceuticals Triple Combination Antiviral Drug Therapy Shows Activity Against Drug-Resistant Influenza Viruses
9. Adamas Pharmaceuticals Signs CRADA With U.S. Navy to Conduct Preclinical Studies of Triple-Combination Antiviral Drug Therapy for Influenza A, Including the Novel H1N1 Pandemic Strain
10. ANA773 Demonstrates Significant Antiviral Response in Early Clinical Trial in Hepatitis C Patients
11. Pharmasset Reports Positive Preliminary Antiviral Data With PSI-7851 for the Treatment of Hepatitis C
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2014)... For its innovative modular Biomedical Research building ... Scientific has earned a Modular Building Institute (MBI) 2014 ... 30 categories, MBI,s contest is the commercial modular industry,s ... manufacturers, dealers, and product and service providers. ... of our team," said Dan Palmer , President ...
(Date:7/31/2014)... VIENNA , July 31, 2014 ... in New York results of AFF008, ... Parkinson,s disease. PD01A is the first therapy against the protein ... The Michael J. Fox Foundation for Parkinson,s Research ... and presented at the press conference on the impact a ...
(Date:7/31/2014)... For the first time, cardiac surgeons, medical ... the SynCardia temporary Total Artificial Heart in a peer ... the Journal of Visualized Experiments website. ... the SynCardia Total Artificial Heart implantation   goo.gl/2OZyKW ... the SynCardia Total Artificial Heart," a July 18, 2014 ...
Breaking Medicine Technology:Art's Way Scientific Earns Prestigious Modular Building Institute Award 2Art's Way Scientific Earns Prestigious Modular Building Institute Award 3Art's Way Scientific Earns Prestigious Modular Building Institute Award 4First Clinical Data of Therapeutic Parkinson's Disease Vaccine Encourages Continued Development 2First Clinical Data of Therapeutic Parkinson's Disease Vaccine Encourages Continued Development 3First Clinical Data of Therapeutic Parkinson's Disease Vaccine Encourages Continued Development 4How to Implant the SynCardia Total Artificial Heart Detailed in Peer Reviewed Paper and Matching Video 2How to Implant the SynCardia Total Artificial Heart Detailed in Peer Reviewed Paper and Matching Video 3
... JOSE, Calif., June 13, 2011 SI-BONE, Inc. (San Jose, ... of a minimally invasive surgical (MIS) device to treat the ... surgeon training milestone for its iFuse Implant System® with over ... in Europe.  As a result, the medical community,s awareness of ...
... MIAMI, June 13, 2011 Sanomedics International Holdings, Inc. (Pink ... Chairman, with Keith Houlihan, Co-founder and President of Sanomedics ... appointment of Charlie Alvarez, Co-founder and President of Watermark ... "The addition of Charlie to the Sanomedics ...
Cached Medicine Technology:Over 400 Surgeons Trained by SI-BONE to Perform Minimally Invasive iFuse Sacroiliac Joint Fusion 2Over 400 Surgeons Trained by SI-BONE to Perform Minimally Invasive iFuse Sacroiliac Joint Fusion 3Over 400 Surgeons Trained by SI-BONE to Perform Minimally Invasive iFuse Sacroiliac Joint Fusion 4Mr. Charlie Alvarez Joins the Board of Sanomedics International Holdings, Inc. 2Mr. Charlie Alvarez Joins the Board of Sanomedics International Holdings, Inc. 3
(Date:7/31/2014)... 2014 Jeremiah’s Tavern ... wood to create a unique atmosphere and highlight ... features reclaimed barn siding on the ... mixed softwoods flowing throughout the interior as flooring. ... sister company New Energy Works Timberframers ...
(Date:7/31/2014)... 31, 2014 US Hair Restoration Founder, Dr. ... be known as Parsa Mohebi Hair Restoration. Since first ... patients in Southern California and around the world, who traveled ... and Orange County. These patients achieved the full benefits of ... that were perfected by Dr. Mohebi. They have come ...
(Date:7/31/2014)... Ce-Classes.com has developed a Learning Management ... to pass inspections and audits. Ce-Classes.com can ... accreditation and state licensing criteria by providing their ... administrators can monitor employee compliance with mandatory training ... can be developed based on the policies and ...
(Date:7/31/2014)... 31, 2014 Current residents at ... program in Flagstaff, AZ, learn to kayak safely for ... and paddle strokes in preparation for next week's wilderness ... think that [the kayaking course] teaches [residents] to listen ... with in their early part of their sobriety," said ...
(Date:7/31/2014)... 31, 2014 Located on one of the ... The Rothenberg Law Firm LLP has moved its office to ... The Rothenberg Law Firm has been handling catastrophic personal injury ... by growth in the firm’s continued success in seeking justice ... York office has a team of experienced and successful trial ...
Breaking Medicine News(10 mins):Health News:Popular Tavern Restaurant Features Pioneer Millworks’ Reclaimed Wood in New Locations 2Health News:US Hair Restoration Becomes Parsa Mohebi Hair Restoration 2Health News:Company Helps Healthcare Agencies to Pass Inspections and Audits 2Health News:Company Helps Healthcare Agencies to Pass Inspections and Audits 3Health News:Back2Basics Substance Abuse Residents Take Kayaking Class for the First Time 2
... Group to Release Groundbreaking Study on Economic Impact of Life ... State SEATTLE, April 20 An alliance ... launch "We Work for Health," a landmark statewide effort to ... life sciences industry and to promote the growth and success ...
... 20 Stryker Corporation (NYSE: SYK ) reported operating ... Quarter Highlights , , ... basis (2.0% decrease as reported) to $1,601 million , ... constant currency basis (0.2% increase as reported) , ...
... common thread among all 3 conditions , , MONDAY, April ... credence to a long-suspected connection between psoriasis, diabetes and ... the Archives of Dermatology suspect the link ... is associated with all three conditions. , "We were ...
... need to make very difficult choices, such as deciding to ... in the Journal of Consumer Research delves into ... or doctors to make those "tragic choices." , Authors ... Iyengar (both Columbia University) say that from the time of ...
... HCA today announced the recipients of the ... a Physician Assistant at Wesley Medical Center in ... Northside Hospital in Macon, Ga., and Laurence Lesser, ... Center in Snellville. Ga., were honored today during ...
... WASHINGTON, April 20 In a recent study, ... blood into cells that are molecularly and functionally ... that provides a readily accessible source of stem ... cells. The findings were prepublished online in ...
Cached Medicine News:Health News:Life Sciences Leaders to Launch Statewide 'We Work for Health' Economic Development and Jobs Campaign 2Health News:Stryker Operating Results for Quarter Ended March 31, 2009 2Health News:Stryker Operating Results for Quarter Ended March 31, 2009 3Health News:Stryker Operating Results for Quarter Ended March 31, 2009 4Health News:Stryker Operating Results for Quarter Ended March 31, 2009 5Health News:Stryker Operating Results for Quarter Ended March 31, 2009 6Health News:Stryker Operating Results for Quarter Ended March 31, 2009 7Health News:Stryker Operating Results for Quarter Ended March 31, 2009 8Health News:Having Psoriasis Raises Risk of Diabetes, Hypertension 2Health News:Tragic choices: Is it better for doctors or patient families to decide? 2Health News:HCA Announces National 2008 Frist Humanitarian Award Recipients 2Health News:HCA Announces National 2008 Frist Humanitarian Award Recipients 3Health News:Study Finds Blood Cells Can Be Reprogrammed to Act as Embryonic Stem Cells 2Health News:Study Finds Blood Cells Can Be Reprogrammed to Act as Embryonic Stem Cells 3
... absolute knowledge. Access it with ... Diagnostic Workstation, uniting two trusted ... and Orbscan IIz Anterior Segment ... critically important data. Together they ...
... LADARWave® device gives you ... measure and display the ... individual eye. This capability ... a better understanding of ...
ZYMAR™ ophthalmic solution is an anti-infective prescription eye drop that your doctor may instruct you to use if you have an eye infection caused by bacteria. Bacterial conjunctivitis is the e...
...
Medicine Products: